Science

Articles

• Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022
  28 October 2020, by Elodie DORMES

  Michel KHRESTCHATISKY will be part of the roundtable 4 and will present the company latest results in connection with “Maintaining and increasing performance – intelligent human machine interfaces, brain tech, exoskeletons, human factor, psychology… ”
  You can access to the program by following the link: https://sante-espace.com/

• Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
  22 March 2022, by Elodie DORMES

  Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

• AAT-AD/PD Focus Meeting, TORINO Italy
  28 January 2019, by Jonathan NOWAK

  Meet Marion DAVID Vect-Horus’ Vector Discovery platform Manager during the AAT-AD/PD Focus Meeting.
  This Alzheimer’s disease conference and Parkinson’s disease conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
  More informations

• Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial partnerships. Dr. Jamal Temsamani is also a member of the Management Committee of VECT-HORUS.

• NTSR2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats
  30 September 2021, by Elodie DORMES

  Neurotensin (NT) acts as a primary neurotransmitter and neuromodulator in the CNS and has been involved in a number of CNS pathologies including epilepsy. NT mediates its central and peripheral effects by interacting with the NTSR1, NTSR2, and Sort1/NTSR3 receptor subtypes. To date, little is known about the precise expression of the NT receptors in brain neural cells and their regulation in pathology. In the present work, we studied the cellular distribution of the NTSR2 protein in the rat (…)

• Vect-Horus announces the expansion of its Scientific Advisory Board
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS is a French biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents into the brain and other organs, and in particular in tumours. VECT-HORUS announces the expansion of its Scientific Advisory Board (SAB). Chaired by Prof. Jean-Michel SCHERRMANN, this Scientific Council is composed of several personalities and opinion leaders of international renown. (…)

• Vect-Horus and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)
  28 January 2019, by Jonathan NOWAK

  and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).

• Vect-Horus Appoints Dr Jean-Manuel PEAN as Chief Scientific Officer
  3 April 2023, by Elodie DORMES

  Marseille, April 3rd, 2023 - VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer. In this role, he will lead the Company’s scientific programs and will be a member of the Management Committee of Vect-Horus.
  Alexandre Tokay, CEO and co-founder of VECT-HORUS said: "We are very pleased to have Jean-Manuel as our (…)

• Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
  28 January 2019, by Jonathan NOWAK

  (Molino et al., 2017, The FASEB Journal)
  www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

• TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
  31 October 2019, by Elodie DORMES

  Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.